Matthew Sender
Seminars
Tuesday 9th March 2027
Advancing In Vitro Model Selection for Bone Marrow, Liver & Lung to Test Pre Clinical Activity & Toxicity
- LCB43: A next-generation beta glucuronide BCMA ADC for the treatment of multiple myeloma
- Belantamab Mafodotin is a great ADC held back by ocular toxicity
- LigaChem’s ConjuAll platform has clinical evidence of less ocular tox
- LCB43 is a next-generation ADC to address the key limitation of Blenrep
